Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 21, 2013; 19(47): 9104-9110
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9104
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9104
Table 4 Therapeutic effect evaluated according to Response Evaluation Criteria in Solid Tumors at 1 mo after treatment n (%)
Group | CR | PR | SD | PD | Effective rate (CR + PR + SD) |
Test group | 4 (4.11) | 38 (39.73) | 26 (27.40) | 27 (28.77) | 68 (71.23) |
Control group | 1 (1.11) | 14 (15.56) | 20 (22.22) | 55 (61.11) | 35 (38.89) |
- Citation: He Q, Lu WS, Liu Y, Guan YS, Kuang AR. 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 9104-9110
- URL: https://www.wjgnet.com/1007-9327/full/v19/i47/9104.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i47.9104